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Background: Lead is a metal with many recognized adverse health side effects, and yet the molecular processes
underlying lead toxicity are still poorly understood. Quantifying the injurious effects of lead is also difficult because
of the diagnostic limitations that exist when analyzing human blood and urine specimens for lead toxicity.
Results: We analyzed the deleterious impact of lead on human cells by measuring its effects on cytokine
production and gene expression in peripheral blood mononuclear cells. Lead activates the secretion of the
chemokine IL-8 and impacts mitogen-dependent activation by increasing the secretion of the proinflammatory
cytokines IL-6 and TNF-α and of the chemokines IL-8 and MIP1-α in the presence of phytohemagglutinin. The
recorded changes in gene expression affected major cellular functions, including metallothionein expression, and
the expression of cellular metabolic enzymes and protein kinase activity. The expression of 31 genes remained
elevated after the removal of lead from the testing medium thereby allowing for the measurement of adverse
health effects of lead poisoning. These included thirteen metallothionein transcripts, three endothelial receptor B
transcripts and a number of transcripts which encode cellular metabolic enzymes. Cellular responses to lead
correlated with blood lead levels and were significantly altered in individuals with higher lead content resultantly
affecting the nervous system, the negative regulation of transcription and the induction of apoptosis. In addition,
we identified changes in gene expression in individuals with elevated zinc protoporphyrin blood levels and found
that genes regulating the transmission of nerve impulses were affected in these individuals. The affected pathways
were G-protein mediated signaling, gap junction signaling, synaptic long-term potentiation, neuropathic pain
signaling as well as CREB signaling in neurons. Cellular responses to lead were altered in subjects with high zinc
protoporphyrin blood levels.
Conclusions: The results of our study defined specific changes in gene and protein expression in response to lead
challenges and determined the injurious effects of exposures to lead on a cellular level. This information can be
used for documenting the health effects of exposures to lead which will facilitate identifying and monitoring
efficacious treatments for lead-related maladies.
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Lead (Pb) is a widely distributed industrial metal and it
also is naturally present in the environment. It is an en-
vironmentally persistent element and a major global en-
vironmental hazard. The Centers for Disease Control
(CDC) currently consider lead poisoning the leading en-
vironmental health threat to children in the US. Lead-
based paint is a primary source of lead exposure and the
major source of lead toxicity in children. Lead exposure* Correspondence: igavin@uic.edu
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reproduction in any medium, provided the oralso remains one of the leading causes of workplace
illness [1].
Lead contamination mainly occurs through absorption
via the respiratory and gastrointestinal systems. Ap-
proximately 30-40% of inhaled lead enters the blood-
stream [2]. Once absorbed, 99 percent of lead is retained
in the blood for approximately 30-35 days and over the
following 4-6 weeks it is dispersed and accumulated in
other tissues – liver, renal cortex, aorta, brain, lungs,
spleen, teeth and bones [3]. The half-life of lead in brain
tissue is about two years and in bones it persists for 20-30
years [4]. Liver tissue is the largest repository of lead
(33%) followed by the kidney cortex and medulla [5].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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versely affect the nervous system, kidneys, the im-
mune system, reproductive and developmental
systems and the cardiovascular system. Its toxic
effects vary from subtle changes in neurocognitive
function in low-level exposures to a potentially fatal
encephalopathy in acute lead poisoning [1]. Infants
and young children are especially sensitive to low
levels of lead which may contribute to behavioral
problems, learning deficits and lowered IQ.
The molecular mechanisms of lead toxicity are still
not clearly defined. The effects of lead on calcium fluxes
and calcium-regulated events have been suggested as
major mechanisms of lead neurotoxicity [6-8]. Lead also
stimulates calmodulin and cAMP phosphodiesterase and
enhances calmodulin-mediated protein phosphorylation
in synaptic vesicles ([4] and references therein), thereby
interfering with calcium/calmodulin-mediated neuro-
transmitter release. Another potential mechanism of lead
toxicity is the ability of lead to induce oxidative stress.
The deleterious effects of lead exposures can involve
both the generation of reactive oxygen or nitrogen spe-
cies (ROS) and a direct depletion of the antioxidant
reserves (reviewed in [9]). Lead decreases glutathione levels
by directly binding to thiol groups and inhibiting glutathi-
one reductase [10]. Lead also inhibits δ-aminolevulinic acid
dehydrogenase (ALAD) resulting in increased levels of
δ-aminolevulinic acid (ALA) which is known to stimulate
ROS production [11]. Lead also can stimulate membrane
lipid peroxidation by binding to phosphatidylcholine in the
cellular membrane and inducing changes in membrane bio-
physical properties [12,13]. ROS production and the gener-
ation of other potentially genotoxic compounds are
possible mechanisms of the carcinogenicity of lead [9].
The diagnosis of lead poisoning has traditionally relied
on measuring blood lead and zinc protoporphyrin levels.
It is commonly accepted that the blood level concentra-
tion is the single best indicator of recent lead exposure
[14]. The U.S. Centers for Disease Control established a
10μg/dL lead concentration in blood as the concern
limit for exposures in children [15]. The blood lead level
rises within hours of exposure and remains elevated for
several weeks thereafter [16]. Due to lead’s short half-life
time in the blood, blood lead tests cannot be used to
diagnose or rule out evidence of exposure that occurred
more than six weeks before testing. Zinc protoporphyrin
or free erythrocyte protoporphyrin accumulates in ery-
throcytes as a result of the inhibition of heme synthesis
[17]. Protoporphyrin levels begin to rise when blood lead
levels exceed 1.5 to 2 μM and remain elevated for sev-
eral months after exposure [18]. The protoporphyrin test
is not as sensitive as the direct measurement of lead
levels as other inhibitors of heme biosynthesis or iron
deficiency anemia also increase protoporphyrin levels[19]. The genetic deficiency of ferrochelatase, a heme
biosynthetic enzyme may lead to inaccurate test results
as well [20].
Measurements of lead in tissues are useful in estimat-
ing exposure doses but they do not document injurious
effects from the amount of lead that was absorbed by the
body. Consequently, a methodology to track and quantify
the injurious effects of exposures to lead is not only de-
sirable, it is critical in order to identify appropriate pre-
ventive and therapeutic methodologies. And because the
injurious effects of lead are often not recognized until
the disease has advanced, identifying subclinical effects
of exposures to lead is vital for early intervention. In an
attempt to identify the biological effects of exposures to
lead as well as develop and test the methodology for
evaluating lead's injurious consequences at a cellular
level, we performed global gene expression profiling in
human cells challenged to lead. In our recent studies, we
have previously utilized this methodology to comprehen-
sively assess unique responses to environmental toxins
in cultured peripheral blood mononuclear cells (PBMC)
[21,22]. In this study we identified the cellular pro-
cesses and pathways which were affected by exposures




We recruited a group of 44 subjects who did not have
any known occupational exposures to lead and none had
ever been diagnosed with lead-related disorders. The
serum lead levels in the group were in a range from 0.1
to 5.8 μg/dL, with an average of 2.13 μg/dL. ZPP levels
in the blood of the subjects ranged from 15-101 μg/dL
with an average of 42.7 μg/dL. Since normal levels for
blood zinc protoporphyrin are defined as being in the
range of 16-36 μg/dL [23], a significant portion of the
test subjects had elevated ZPP test results.
Cytokine expression
To determine how lead affects PBMC functions, we ana-
lyzed the impact of lead acetate on the secretion of 15
common cytokines by PBMC. The majority of the cyto-
kines were below the lower detection limit and only che-
mokines IL-8, MIP-1β, MCP-1, Eotaxin, MIP-1α and
RANTES were detected in the PBMC culture superna-
tants (not shown). Challenging cells with lead acetate at
concentrations 10μM and above resulted in a dose-
dependent increase of IL-8 production (Figure 1A). We
also examined the effects of lead acetate on the
mitogen-activated expression of cytokines. PHA stimu-
lated production of all 15 cytokines in the control cul-
tures which resulted in a significant increase in cytokine
levels [21,22]. Lead acetate further increased the PHA-
AB
Figure 1 Cytokine production by PBMC challenged to lead acetate. Concentrations of cytokines in PBMC cultures challenged to either lead
acetate alone at indicated concentrations (A) or to lead acetate in combination with 1μg/ml PHA (B) were normalized to those in control
cultures. Statistically significant changes are marked with asterisks.
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TNF-α and chemokines IL-8, and MIP-1α (Figure 1B). The
highest increase of cytokine levels was at 50 μM lead acet-
ate and some effect was also detected at 10 μM.
These results demonstrated that lead increases mito-
genic activation of PBMC, which is in agreement
with the lead-dependent stimulation of lymphocyte
and leukocyte proliferation and function observed in
earlier studies [24-27].
Gene expression profiling in PBMC challenged to lead
The cytokine expression study identified the specific im-
pact of lead on mononuclear cell functions. To better
understand how exposures to lead affect cellular pro-
cesses on a molecular level and in order to identify
intracellular responses to lead, we performed a genome-
wide expression profiling in the PBMC of seven healthy
individuals challenged to 10 μM lead acetate, the lowest
concentration which affected cytokine production. Cul-
turing cells in the presence of lead acetate for one day
significantly altered the expression of 271 transcripts, of
which expression of 221 transcripts changed 1.5-fold ormore, including 157 downregulated transcripts and 64
upregulated transcripts. We observed elevated expres-
sions of a number of cellular metabolic enzymes and
metal-binding proteins which are important components
in cellular defense responses against heavy metal insults.
For example, of sixteen transcripts which were elevated
3-fold or more in lead-treated cells, twelve corresponded
to seven metallothionein (MT) genes and the MT
pseudogene. MT is a family of cysteine-rich, low mo-
lecular weight proteins which bind heavy metals through
the thiol group of their cysteine residues [28]. MT pro-
teins are implicated in protecting against metal-induced
toxicity as well as oxidative stress and their expression is
induced by a number of stimuli, including exposures to
metals, oxidative stress, glucocorticoids, hydric stress
and others [29,30].
To determine what cellular functions were most affected
by the exposure to lead, we applied the DAVID functional
bioinformatics resources tool to identify annotation clus-
ters enriched with differentially expressed genes. Two an-
notation clusters containing methallothionein genes were
identified, methallothioneins and cadmium/copper ion
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were also among the functional groups of genes that were








208581_x_at, 204326_x_at metallothionein 1X
216336_x_at, 212859_x_at metallothionein 1L (gene/pseudogene);
metallothionein 1E; metallothionein





211993_at WNK lysine deficient protein kinase 1;
hypothetical LOC100132369
244846_at mitogen-activated protein kinase
kinase kinase kinase 4
214464_at CDC42 binding protein kinase
alpha (DMPK-like)
241403_at CDC-like kinase 4
213328_at NIMA (never in mitosis gene
a)-related kinase 1Residual effect of exposures to lead
Exposures to lead of human PBMC adversely affected
their functions as evidenced by the changes in gene ex-
pression. However, these changes may reverse when
lead is no longer available in the medium. To investi-
gate the residual, adverse effects of lead poisoning on
the cells, we removed lead acetate from the cell cul-
tures and determined the persistent changes in the gene
expression. After an initial incubation with lead acetate
for one day, the cells were washed three times and cul-
tured in fresh RPMI medium without lead acetate for
one additional day, for a total of two days. Gene ex-
pression in these cells from the entire group of 44 indi-
viduals was compared with control cells from the same
group which were cultured under the identical condi-
tions in the absence of lead acetate. We identified 604
transcripts whose expressions were different in these
two groups of cells. 146 transcripts corresponded to
104 genes whose expression increased 1.5-fold or more
in lead-challenged cells, and 58 transcripts corre-
sponded to 39 genes whose expressions decreased 1.5-
fold or more in exposed cells. The observed changes
were consistent with cells recovering from the lead in-
sult and the restoration of their functions. However, it
is likely that the changes in the expression of many
genes resulted from removing lead from the medium.
In order to identify genes whose expressions changed
in response to the lead challenge and remained altered
after removing lead from the cultures, we compared the
lead-dependent changes in one-day cultures and inTable 1 Annotation clusters of genes affected by lead
Annotation Cluster 1 Enrichment Score: 9.7
Category Term
UP_SEQ_FEATURE metal ion-binding site: Divalent metal catio
UP_SEQ_FEATURE metal ion-binding site: Divalent metal catio
PIR_SUPERFAMILY PIRSF002564:metallothionein
INTERPRO IPR018064: Metallothionein, vertebrate, me
SP_PIR_KEYWORDS metal-thiolate cluster
INTERPRO IPR000006: Metallothionein, vertebrate
INTERPRO IPR003019: Metallothionein superfamily, eu
Annotation Cluster 2 Enrichment Score: 5.8
Category Term
SP_PIR_KEYWORDS cadmium
GOTERM_MF_FAT GO:0046870 ~ cadmium ion binding
SP_PIR_KEYWORDS copper
GOTERM_MF_FAT GO:0005507 ~ copper ion bindingtwo-day cultures. We identified 42 transcripts, corre-
sponding to 31 genes whose expressions changed simi-
larly in both groups. Expressions of 38 transcripts
corresponding to 22 genes were at least 2 times higher
than in the control cells. The list of these genes is
shown in Table 3. Eighteen transcripts remained ele-
vated three-fold or more in lead-exposed cells after re-
moving lead from the culture. We observed elevated
levels of all 12 MT transcripts, the pirin transcript (anCount P-value FDR
n; cluster B 7 2.02E-10 3.01E-07
n; cluster A 7 2.02E-10 3.01E-07
7 2.15E-10 2.26E-07
tal binding site 7 2.23E-10 3.05E-07
7 3.86E-10 4.98E-07
7 4.43E-10 6.06E-07






Table 3 Persistent changes in gene expression induced by lead
Gene Symbol Gene Title Probe Set ID Entrez Gene ID Fold Increase P-value
MT1M metallothionein 1M 217546_at 4499 18 1.03E-22
MT1G metallothionein 1G 204745_x_at 4495 17.7 1.64E-27
MT1H metallothionein 1H 206461_x_at 4496 14.2 6.96E-28
MT1X metallothionein 1X 208581_x_at 4501 13.9 1.90E-26
204326_x_at 4501 13 1.66E-25
MT1E metallothionein 1E 212859_x_at 4493 10.9 4.23E-26
MT2A metallothionein 2A 212185_x_at 4502 10.6 2.93E-27
MT1P2 metallothionein 1 pseudogene 2 211456_x_at 645745 9.55 2.96E-27
MT1F metallothionein 1F 217165_x_at 4494 8.86 1.29E-24
213629_x_at 4494 6.6 2.47E-21









EDNRB endothelin receptor type B 204273_at 1910 11 1.11E-17
206701_x_at 1910 6.6 8.42E-13
204271_s_at 1910 5.99 3.32E-13
ALDH1A1 aldehyde dehydrogenase
1 family, member A1
212224_at 216 4.37 6.93E-06
KITLG KIT ligand 226534_at 4254 3.19 2.02E-09
TDO2 tryptophan 2,3-dioxygenase 205943_at 6999 3.14 0.004728
TMEM158 transmembrane protein 158 213338_at 25907 2.96 6.16E-15
FAM70A family with sequence
similarity 70, member A
219895_at 55026 2.87 0.000112
PTGR1 prostaglandin reductase 1 231897_at 22949 2.86 3.65E-08
228824_s_at 22949 2.74 4.81E-07
ARRDC4 arrestin domain containing 4 225283_at 91947 2.8 7.31E-11
AKR1C1 aldo-keto reductase family 1, member C1
(dihydrodiol dehydrogenase 1; 20-alpha)
204151_x_at 1645 2.68 0.000934
216594_x_at 1645 2.28 3.79E-05
AKR1C2 aldo-keto reductase family 1, member
C2 (dihydrodiol dehydrogenase 2; bile acid)
211653_x_at 1646 2.47 4.10E-05
209699_x_at 1646 2.28 5.27E-05
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic 204058_at 4199 2.53 9.73E-07
204059_s_at 4199 2.3 9.20E-08
SLC7A11 solute carrier family 7, (cationic amino acid
transporter, y + system) member 11
207528_s_at 23657 2.58 3.45E-07
209921_at 23657 2.42 7.46E-06
217678_at 23657 2.37 4.72E-05
ASPH aspartate beta-hydroxylase 210896_s_at 444 2.41 1.80E-11
209135_at 444 2.5 3.04E-10
224996_at 444 2.08 9.56E-08
225008_at 444 1.87 4.93E-08
205808_at 444 1.58 7.60E-05
242037_at 444 1.57 1.32E-06
ENSG00000204134 — 238727_at — 2.23 0.000495
SLC12A8 solute carrier family 12 (potassium/chloride
transporters), member 8
219874_at 84561 2.17 1.85E-08
PIR pirin (iron-binding nuclear protein) 207469_s_at 8544 2.01 0.000561
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type B transcripts, aldehyde dehydrogenase 1, the KIT
ligand and the tryptophan 2,3-dioxygenase transcripts.
Other transcripts included four transcripts encoding
dihydrodiol dehydrogenase, six transcripts encoding as-
partate beta-hydroxylase, four transcripts encoding solute
carrier proteins, two transcripts encoding prostaglandin
reductase, transcripts encoding arrestin, and malic en-
zyme. These genes represented a panel of putative cellular
biomarkers which were induced by lead and whose
expressions remained activated after lead was removed
from the medium. Since the changes in expression of
these genes were not transient, they could be utilized for
evaluating exposures to lead.
Cellular responses to lead in subjects with elevated blood
lead levels
A number of studies have demonstrated that lead expo-
sures resulting in blood lead levels below 10 μg/dL may
cause cognitive dysfunction, neurobehavioral disorders,
neurological damage, hypertension and renal impair-
ment [31-33]. To determine if cellular responses to lead
are altered in individuals with elevated blood lead levels
which are still below the safety concern threshold level,
we divided the subjects into three groups based on their
lead test results and compared gene expressions between
these groups. The control “low lead” group consisted of
eight individuals whose blood lead levels were equal to
or below 1μg/dL, with a 0.7 μg/dL mean value. The
“moderate lead” group had nine individuals with blood
lead levels ranging from 2 μg/dL to 3 μg/dL, with a 2.6
μg/dL mean value and the “high lead” group contained
seven subjects with lead test results above 4 μg/dL. The
lead levels in this group ranged from 4.4 μg/dL to 5.8
μg/dL and the mean value was 5.2 μg/dL. Initially, we
compared gene expressions in the control cultures to de-
termine the basal differences in the gene expression pat-
tern between the groups. Gene expressions in the
“moderate lead” and “high lead” group were similar to
the “low lead” group. There was no statistically signifi-
cant difference in the gene expression patterns between
the “moderate lead” and the “low lead” groups and only
one transcript was identified which was upregulated in
the “high lead” group. However, when the cells were
challenged to lead acetate, marked changes in gene
expressions were observed between these groups de-
pending on the blood lead levels. Expressions of 17 tran-
scripts in the “moderate lead” group and expressions of
1440 transcripts in the “high lead group” were altered
compared to the “low lead” group. Eight transcripts in
the “moderate lead” set of 17 differentials were also
present among 1440 transcripts identified in the “high
lead” group. Annotation clustering revealed that the
most affected cellular processes were negative regulationof transcription and the induction of apoptosis (Table 4).
Functional analysis of the gene expression data showed
that nervous system development and function were the
most affected categories in the "high lead" group
(Table 5). These results show that the responses of the
cells were significantly altered in individuals with higher
blood lead levels affecting primarily the nervous system
and supported the view that the blood lead levels lower
than the CDC-recommended concern level have dele-
terious effects on cellular functions.
Gene expression profiling in subjects with elevated ZPP
test results
One of the inclusion parameters for selecting a cohort of
44 subjects was the normal blood lead test result. Unlike
blood lead levels which decrease to normal in several
weeks after exposure, blood ZPP levels remain elevated
for several months [18]. Zinc protoporphyrin levels in
the blood samples of 28 subjects were above the normal
range. It is possible that some individuals may have been
unknowingly exposed to lead in the past and their blood
lead levels returned to normal at the time the test was
taken. To explore this possibility, we determined
whether cellular responses to lead were altered in the
subjects with higher ZPP levels. We placed the subjects
in two groups according to their ZPP test result. The
“high ZPP” group contained fifteen subjects whose ZPP
levels were above normal. In this group, the ZPP test
results ranged from 43 μg/dL to 101 μg/dL and the
mean value was 55 μg/dL. Fifteen subjects in the “nor-
mal ZPP” group had ZPP levels in the normal range,
from 20 μg/dL to 35 μg/dL, with the mean value of 28
μg/dL. The mean blood lead levels in both groups were
3 μg/dL and 1.1 μg/dL, respectively, and the difference
was statistically significant. Initially, we determined the
difference in gene expressions in control cells. We iden-
tified 567 transcripts whose abundance was different in
these two groups. For most transcripts, the ratios of the
signals were below 1.5 and the levels of only 140 tran-
scripts changed 1.5-fold or more. Among the genes that
were downregulated in the “high ZPP” group were
angiopoietin genes as well as genes encoding cyclin 1
and fibroblast growth factor receptor 2. The expressions
of these genes were also inhibited in human cell lines chal-
lenged to ZPP [34]. DAVID annotation clustering analysis
revealed that the most affected cellular process in the
“high ZPP” group was the positive regulation of synaptic
transmission (Table 6). Pathway analysis also identified a
number of groups related to the nervous system. Among
the groups with top ten scores were neuropathic pain sig-
naling, CREB signaling in neurons, neuroprotection in
Alzheimer's disease, Gβγ signaling, gap junction signaling,
and synaptic long term potentiation (Figure 2). Other
groups were related to the immune system.
Table 4 Annotation clusters affected by lead in individuals with high blood lead levels
Annotation Cluster 1 Enrichment Score: 4.6
Category Term Count P-value FDR
GOTERM_BP_FAT GO:0010941~ regulation of cell death 84 2.05E-05 0.04
GOTERM_BP_FAT GO:0042981~ regulation of apoptosis 83 2.21E-05 0.04
GOTERM_BP_FAT GO:0043067~ regulation of programmed cell death 83 3.15E-05 0.06
Annotation Cluster 2 Enrichment Score: 4.4
Category Term Count P-value FDR
GOTERM_BP_FAT GO:0010629~ negative regulation of gene expression 59 1.24E-05 0.02
GOTERM_BP_FAT GO:0016481~ negative regulation of transcription 55 1.33E-05 0.02
GOTERM_BP_FAT GO:0010558~ negative regulation of macromolecule biosynthetic process 62 1.97E-05 0.04
GOTERM_BP_FAT GO:0031327~ negative regulation of cellular biosynthetic process 63 2.22E-05 0.04
GOTERM_BP_FAT GO:0009890~ negative regulation of biosynthetic process 64 2.23E-05 0.04
GOTERM_BP_FAT GO:0045934~ negative regulation of nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process
57 7.26E-05 0.13
GOTERM_BP_FAT GO:0051172~ negative regulation of nitrogen compound metabolic process 57 1.05E-04 0.19
GOTERM_BP_FAT GO:0010605~ negative regulation of macromolecule metabolic process 71 6.31E-04 1.14
Annotation Cluster 3 Enrichment Score: 4.0
Category Term Count P-value FDR
GOTERM_BP_FAT GO:0043068~ positive regulation of programmed cell death 50 9.01E-05 0.16
GOTERM_BP_FAT GO:0010942~ positive regulation of cell death 50 1.00E-04 0.18
GOTERM_BP_FAT GO:0043065~ positive regulation of apoptosis 49 1.47E-04 0.27
Annotation Cluster 4 Enrichment Score: 3.8
Category Term Count P-value FDR
GOTERM_BP_FAT GO:0016481~ negative regulation of transcription 55 1.33E-05 0.02
GOTERM_BP_FAT GO:0045892~ negative regulation of transcription, DNA-dependent 41 4.50E-04 0.81
GOTERM_BP_FAT GO:0051253~ negative regulation of RNA metabolic process 41 6.25E-04 1.13
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vated ZPP levels responded differently to the lead chal-
lenges, we compared gene expressions in the “high ZPP”
group and the “normal ZPP” group in the cell samples
challenged to lead. A total of 1230 transcripts were iden-
tified whose signals were different in the two study
groups by a statistically significant value. Of those, only 275
transcripts had a ratio of mean signal values higher thanTable 5 Physiological processes affected by lead in




8 8.32E-04 - 4.62E-02
Proliferation of Schwann cells 3 8.32E-04
Growth of axons 3 2.50E-02
Axonal transport 2 4.62E-02
Tissue development 18 3.62E-03 - 4.62E-02
Tumor Morphology 9 6.34E-03 - 4.62E-02
Hematological system development
and function
22 9.70E-03 - 4.81E-02
Hematopoiesis 13 9.70E-03 - 3.61E-021.5. 146 transcripts in this group were also identified in
control cultures at the 10% confidence level. Expressions
of the majority of genes therefore varied between these
two groups regardless of a lead challenge. A remaining
129 transcripts were found only in the cells challenged
to lead and signified the difference in the responses to
lead between the “high ZPP” group and the “normal
ZPP” group (Additional file1: Table S1). These results
demonstrated that cellular responses to lead were altered
in subjects with elevated blood ZPP levels.Discussion
For many chronic diseases, the specific role of environ-
mental exposures in causing diseased phenotypes is not
well understood. It is vital to determine when injurious
exposures have occurred long before there is the appear-
ance of overt clinical signs and symptoms in humans.
Because these injurious effects most certainly develop in
a discrete cellular manner, we applied gene expression
and protein profiling to find and categorize these cellular
effects. Cytokine profiling, in particular, is very import-
ant for understanding how environmental exposures
affect the expression of these soluble mediators which
Table 6 Annotation clusters of genes affected in individuals with higher ZPP levels
Annotation Cluster 1 Enrichment Score: 2.8
Category Term Count P-Value Fold Enrichment FDR
GOTERM_BP_FAT GO:0050806 ~ positive regulation of synaptic transmission 6 0.0013 7.3 2.1
GOTERM_BP_FAT GO:0051971 ~ positive regulation of transmission of nerve impulse 6 0.0018 6.7 3.1
GOTERM_BP_FAT GO:0031646 ~ positive regulation of neurological system process 6 0.0023 6.3 3.9
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ferentiation and repair processes [35]. Even low-level
exposures to lead impair cell-mediated immunity by up-
setting the balance between Th1- and Th2- like T lym-
phocytes which alters cytokine expression [36-38]. The
changes in proinflammatory cytokines also play a role in
the neurotoxicity of lead [39-41]. We demonstrated that
lead exposures resulted in a dose-dependent increase of
IL-8 production by PBMC as well as enhanced the pro-
duction of the proinflammatory cytokines IL-6, TNF-α
and the chemokines IL-8 and MIP-1α in response to
mitogens. The increase in the TNF-α level was in agree-
ment with previous studies [42] and was consistent with
epidemiological data on lead-exposed workers [43]. Our
observation that lead increases mitogenic activation of
PBMC was in agreement with the activation of lympho-
cyte and leukocyte proliferation and function by lead
which has been observed in earlier studies [24-27]. One
mechanism by which lead may activate PBMC is by in-
ducing PKC-dependent cell signaling cascades [4]. Our
findings demonstrated that exposure to lead strongly
affects cell signaling pathways, particularly ATP binding
and kinase activity.
In an attempt to find changes in gene expression fol-
lowing exposures to lead, we identified genes whose activation 
/  signaling 
B cell development
Systemic lupus erythematosus signaling 
Neuropathic pain signaling in dorsal horn 
PPAR /RXR
CREB signaling in neurons 
mary immunodeficiency signaling 





Gap junction signaling 
Synaptic long term potentiation
Figure 2 Physiological processes affected by lead challenge in subjec
scores (blue bars). Yellow graph corresponds to the ratio of the number ofexpressions were induced by lead and remained activated
even after the lead was removed from the media. The
most pronounced effect was the activation of the expres-
sion of metallothionein (MT) genes. MT gene expression
has been identified and utilized as a biomarker of heavy
metal exposures in a variety of biological systems [44-51]
including in human cell lines [52] as well as in exposures
to cadmium in humans [53]. Our findings imply that
expressions of metallothionein genes in human tissues
also may be applied to assessing exposures to lead. An-
other gene whose expression was activated by lead was
the endothelin receptor B (EDNRB). Although the mech-
anism of EDNRB regulation by lead is unknown, an in-
crease of its expression may contribute to the
hypertension observed in low-level lead exposures [54].
A number of metabolic enzymes were also upregulated
by lead exposures, including the genes encoding alde-
hyde dehydrogenase, tryptophan 2,3-dioxygenase, malic
enzyme, aspartate beta-hydroxylase, prostaglandin re-
ductase 1 and two members of the aldo-keto reductase
family 1, C1 and C2. All of these enzymes with the ex-
ception of tryptophan 2,3-dioxygenase and aspartate
beta-hydroxylase are NAD(P) + dependent. Tryptophan
2,3-dioxygenase catalyzes the degradation of tryptophan
into N-formyl-kynurenine. Tryptophan depletion andts with high blood ZPP content. The categories were sorted by their
affected genes to the total number of genes in this category.
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rest and apoptosis of T lymphocytes, thereby suppres-
sing T-cell activation [55,56]. They also promote the
differentiation of naive CD4+ T cells into regulatory T
cells. An increase in the expression of this enzyme as a
result of exposure to lead may explain the depletion of
CD4+ T cells observed in exposed individuals [57-60].
An increased production of tryptophan metabolites was
also implicated in neurodegenerative disorders [61]. For
example, an increase of tryptophan 2,3-dioxygenase ex-
pression was found in astrocytes of schizophrenic
patients [62]. Lead-dependent activation of the gene en-
coding this enzyme may contribute to the neurocogni-
tive symptoms which are observed in lead-exposed
individuals. Another possible mechanism by which expo-
sures to lead can impair neurocognitive function is the
dysregulation of neurosteroids. The Aldo-keto reductase
family 1 enzymes, AKR1C1 and AKRC2 are implicated
in steroid metabolism. AKRC1 inactivates progesterone
by forming 20α-hydroxyprogesterone [63,64]. Progester-
one and its neuroactive metabolites have modulatory
effects on brain function and influence social, cognitive,
emotional and physical processes [65,66]. Increased ex-
pression of AKR1C as a result of exposures to lead may
change the levels of progesterone and its neuroactive
metabolites, such as 3α,5α-THP, thereby contributing to
neurocognitive disorders. Upregulation of the xenobiotic
metabolizing enzymes AKR1C1 and AKRC2 caused by
lead was also observed in primary normal human bron-
chial epithelial cells [67].
Among the enzymes that were upregulated in the cells
challenged to lead were prostaglandin reductase 1, which
inactivates leukotriene B4; 15-ketoprostaglandins which
are important mediators of inflammation [68,69]; aspar-
tate beta-hydroxylase, which plays an important role in
calcium homeostasis [70]; malic enzyme, a cytosolic,
NADP-dependent enzyme which generates NADPH for
fatty acid biosynthesis [71]; and a cytosolic isoform of al-
dehyde dehydrogenase 1, an enzyme in the major oxida-
tive pathway of alcohol metabolism [72]. Other activated
genes included transcriptional cofactor pirin, an iron-
binding nuclear protein involved in apoptosis [73]; two
members of the amino acid/polyamine transport system,
SLC12A8A [74] and SLC7A11 [75]; KIT ligand, the lig-
and of the tyrosine-kinase receptor encoded by the KIT
locus, implicated in pigmentation [76] and cancer [77];
α-arrestin 4 [78]; transmembrane protein TMEM158;
FAM70A and putative protein ENSG00000204134. Our
findings that expressions of these genes were not transient
and remained elevated even after the lead was removed
from the system, demonstrate that they could be utilized as
biomarkers in tests for assessing exposures to lead.
The U.S. Centers for Disease Control set a threshold
for a significant exposure to lead at blood lead levels of10 μg/dL or above which have an increased risk for
both subclinical and overt effects from this substance
[15]. In particular, individuals with a blood lead level
of 10 μg/dL or above are at high risk for peripheral
neuropathies and/or chronic nephropathies, with the
latter often triggering consequential hypertension. The
analysis of the gene expressions demonstrated that cel-
lular responses to lead were significantly altered in
individuals with blood lead levels around 5 μg/dL, sug-
gesting that doses lower than 10 μg/dL impair cellular
functions. The most affected system was the nervous
system and the most affected groups were the negative
regulation of transcription and the positive regulation
of apoptosis. The changes in gene expressions corre-
lated well with the blood lead levels and were in
agreement with previous studies in children [79].
Although the blood lead test provides accurate infor-
mation on lead absorption in persons with brief acute
exposures, it cannot be used for assessing past or
chronic exposures. It is well known that exposures to
lead are also associated with elevated blood ZPP levels
which remain elevated for several months after the ex-
posure. The analysis of blood chemistries in 44 sub-
jects demonstrated that elevated blood ZPP levels
correlated with higher blood ZPP content. Expressions
of genes encoding proteins involved in the transmis-
sion of nerve impulses were significantly affected in
the “high ZPP” group. Among the affected pathways
were G-protein mediated signaling, gap junction signal-
ing, synaptic long-term potentiation, neuropathic pain
signaling as well as CREB signaling in neurons (Figure 2).
Therefore, the nervous system was highly affected
in these individuals confirming clinical observations
[31-33].
Blood ZPP levels are increased in individuals who are
deficient in mineral iron or metabolism [19,80], there-
fore ZPP measurements only provide indirect evidence
of an exposure to lead. Nevertheless, the cellular
responses to lead were changed in the subjects with the
elevated blood ZPP levels which were signified by the
altered gene expression profiles.
Conclusions
The present study defined discrete and unique responses
to lead in cultured PBMC. Our findings define the in-
jurious effects from lead exposures at the cellular level.
The methodology of detecting the health effects of envir-
onmental exposures based upon individual cellular re-
sponse patterns offers a starting point for assessing
injurious consequences of such exposures and to devel-
oping appropriate health treatment protocols. This ap-
proach makes it possible to obtain human toxicity data
which can be used to identify the potentially injurious
effects of exposures to any occupational and
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are not yet available. Human medical toxicology is based
upon the appreciation that after target cells of a toxin
are impacted, there are two primary phases of reaction.
One is composed of the acute side effects, which are
then followed by the chronic and residual impact of the
toxin. We have been able to document both the “acute”
and “residual” effects of lead on human cells based upon
changes in gene expression patterns. We believe that
gene expression profiling can be utilized whenever there
is a desire to confirm lead poisoning and it therefore
merits being an adjunct to blood lead testing in lead-
exposed individuals, particularly in those in which an ad-
verse impact needs to be ascertained.
Methods
Human subjects
The study was approved by the Institutional Review
Board Services, Aurora, Ontario, Canada. We recruited
44 healthy volunteers from the Los Angeles, CA area.
Volunteers were of both genders ranging in age between
18 and 54 and equally distributed among Caucasians,
Hispanics, African Americans and Asians. The subjects
signed the consent forms, completed the health ques-
tionnaire forms and underwent physical examinations.
Those who had no history of known personal or occupa-
tional exposures to lead and no background of lead-
related symptoms or disorders underwent blood tests to
determine their plasma lead and ZPP levels. The sub-
jects whose plasma lead levels were in the normal range
below 10 μg/dL were asked to provide 50 ml of blood
for experimentation.
Isolation and culture of PBMC
The blood was collected in (K3) EDTA collection
tubes by venipuncture after obtaining appropriate
informed consent. PBMC were isolated by Ficol gradi-
ent centrifugation as described earlier [21,22] and were
suspended at 106 cells/ml in RPMI 1640 medium supple-
mented with 1% penicillin-streptomycin, 1% L-glutamine
and 10% fetal bovine serum (Invitrogen, Carlsbad, CA).
The cells were cultured for 18 hours in three replicate
plates in the presence of lead acetate at five concentrations:
0.08 μM, 0.4 μM, 2 μM, 10 μM and 50 μM either with or
without 10μg/ml phytohemagglutinin (PHA-P, Sigma-
AldrichW, St. Louis, MO). Control cells were cultured in
three replicate wells in the medium which did not contain
lead. Lead concentrations were far below the toxicity
levels observed in PBMC at concentrations above
500 μM [81].
Cytokine assay
Cell culture supernatants were collected and concen-
trations of 15 common cytokines GM-CSF, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, TNF-α, MIP-1β,
MCP-1, Eotaxin, MIP-1α and RANTES were measured
by using multiplex immunoassays based on Luminex
xMAP™ bead array technology as described earlier
[21,22]. PBMC isolated from three donors were used
for the cytokine analyses. Mean concentration values
of cytokines in cultures challenged to lead acetate were
normalized to those in control cultures. The normal-
ized values at 10 μM and 50 μM lead acetate were
compared to those at 0.08 μM and 0.4 μM lead acet-
ate by pooled t-tests. The variances in the groups were
confirmed by the F-test. All F-test p-values were above
0.1, except for IL-8 at 50 μM lead acetate. T-test with
the Satterthwaite approximation to the degrees of free-
dom was used for this challenge. All t-tests assumed
two-tailed distribution and the confidence level was set
at 5%.
RNA isolation and gene array analysis
Total RNA was purified from PBMC samples by
using Trizol reagent and RNeasy RNA purification
kits (Qiagen Sciences, Valencia, CA) according to the
manufacturer's instructions. Whole genome expres-
sion profiling was performed by using Human Genome
U133 Plus 2.0 GeneChipW arrays (Affymetrix, Santa Clara,
CA) interrogating over 47,000 transcripts from approxi-
mately 40,000 annotated human genes. All labeling reac-
tions and hybridizations were carried out according to the
Affymetrix GeneChipW eukaryotic target labeling protocol.
Bound probes were detected by laser excitation of the fluor-
escent markers and the resultant emission spectra were
obtained by using the Gene Array Scanner 3000
(Agilent Technologies, Santa Clara, CA). Data acquisi-
tion was performed using GCOS (Affymetrix Gene-
Chip Operating Software Package). Data normalization,
background correction and all subsequent statistical tests
for significant differential expressions were performed by
using a Partek statistical software package (Partek., Inc, St.
Louis, MO). Data was normalized via a quintiles
normalization and summarized using the Robust Multi-
array Average (RMA) method [82]. The ANOVA test
was used to calculate the significance of the differen-
tial expression between treated and untreated sam-
ples. Raw p-values were corrected for FDR (false
discovery rate) using the Benjamini and Hochberg
procedure [83] and a cut-off level equal or less than
0.05 was applied. Cluster analysis was performed by
using the DAVID functional annotation tool [84].
Additional functional analysis was performed by
using an Ingenuity Pathway Analysis software (In-
genuity Systems, Redwood City, CA). Gene array
data were deposited in the Gene Expression Omni-
bus database, accession number GSE37567 [85].
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